Immunogenicity of BNT162b2 mRNA SARS-CoV-2 vaccine in patients with psoriatic arthritis on TNF inhibitors

Venerito, Vincenzo; Stefanizzi, Pasquale; Fornaro, Marco; Cacciapaglia, Fabio; Tafuri, Silvio; Perniola, Simone; Iannone, Florenzo; Lopalco, Giuseppe

doi:10.1136/rmdopen-2021-001847

Cited by 23 publications

(24 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In conclusion, we evidenced a good safety profile of anti-SARS-CoV-2 vaccine in a large cohort of patients affected by IIM. Our findings, which are in line with real-life data coming from patients with other diseases, have found a clinical non-statistically significant risk of relapse in our patients, which occurred seldom, usually mild and in the ones with a more severe and aggressive course of disease: indeed, the only patient who died suffered from a severe, long-standing PM poorly responsive to the treatment Such findings are comparable with the literature data available about other rheumatologic disorders [ 30 , 42 ].…”

Section: Discussionsupporting

confidence: 92%

See 1 more Smart Citation

Relapses of idiopathic inflammatory myopathies after vaccination against COVID-19: a real-life multicenter Italian study

et al. 2022

Self Cite

View full text Add to dashboard Cite

Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) vaccination plays a crucial role as pivotal strategy to curb the coronavirus disease-19 (COVID-19) pandemic. The present study described the clinical status of patients affected by idiopathic inflammatory myopathies (IIM) after COVID-19 vaccination to assess the number of relapses. We included all patients affected by IIM and followed by Myositis Clinic, Rheumatology and Respiratory Diseases Units, Siena University Hospital, Bari University Hospital, Policlinico Umberto I, Sapienza University, Rome, and Policlinico Paolo Giaccone, Palermo. They underwent a telephone survey. A total of 119 IIM patients (median, IQR 58 (47–66) years; 32males; 50 dermatomyositis, 39 polymyositis and 30 anti-synthetase syndrome) were consecutively enrolled. Except four patients who refused the vaccination, 94 (81.7%) received Comirnaty, 16 (13.9%) Spikevax, 5 (4.4%) Vaxzevria. Seven (6.1%) patients had flare after vaccination. One of them had life-threatening systemic involvement and died two months after second dose of COVID-19 vaccination. From logistic regression analysis, Chi2-log ratio = 0.045,the variable that most influences the development of flare was the number of organs involved (p = 0.047). Sixty-eight patients received the third dose of COVID-19 vaccination: 51(75%) Comirnaty and 17 (25%) Moderna. No patients had flares after third dose. Our study represents the largest cohort of IIM patients in which the incidence of recurrence after anti-SARS-CoV-2 vaccine was assessed. In line with real-life data from other diseases, we found a clinical non-statistically significant risk of relapse in our patients, which occurred seldom, usually mild and in patients with a more severe and aggressive course of disease.

show abstract

Section: Discussionsupporting

confidence: 92%

“…Nevertheless, vaccines seem to be a safe option in rheumatic patients, as large studies, performed in wide cohorts, have not shown any significant risk of relapse in this particular subset of patients [27][28][29][30], even when affected by rare diseases [31,32].…”

Section: Discussionmentioning

confidence: 99%

Relapses of idiopathic inflammatory myopathies after vaccination against COVID-19: a real-life multicenter Italian study

et al. 2022

Self Cite

View full text Add to dashboard Cite

show abstract

“…These findings appear to be in line with previous research highlighting an altered immune response against various microbial species and after vaccine administration( 11 ). A similar pattern of response resembles that observed also in other conditions of immunosuppression( 12 ).…”

Section: Discussionsupporting

confidence: 88%

SARS-CoV-2 vaccine humoral response in adults with Down syndrome

Sali

Carfì

Paola

et al. 2022

Clinical Microbiology and Infection

View full text Add to dashboard Cite

“…For biologics that inhibit certain cytokines (e.g., tumor necrosis factor, interleukin‐6 receptor [IL‐6R], IL‐1R, IL‐17, IL‐12/23, IL‐23), the task force failed to reach consensus on whether or not to temporarily interrupt these following each COVID‐19 vaccine dose. Some panel members felt that withholding treatment for 1–2 weeks was unnecessary, had minimal effect on vaccine response ( 68 , 99 ), and could put the patient at greater increased risk for disease to worsen. In contrast, other task force members felt that even limited evidence suggesting the possibility that these therapies could attenuate vaccine response should result in a recommendation of a temporary interruption of therapy ( 100 , 101 ).…”

Section: Resultsmentioning

confidence: 99%

American College of Rheumatology Guidance for COVID‐19 Vaccination in Patients With Rheumatic and Musculoskeletal Diseases: Version 4

Curtis

Johnson

Anthony

et al. 2022

Arthritis & Rheumatology

View full text Add to dashboard Cite

To provide guidance to rheumatology providers on the use of COVID-19 vaccines for patients with rheumatic and musculoskeletal diseases (RMDs).Methods. A task force was assembled that included 9 rheumatologists/immunologists, 2 infectious disease specialists, and 2 public health physicians. After agreeing on scoping questions, an evidence report was created that summarized the published literature and publicly available data regarding COVID-19 vaccine efficacy and safety, as well as literature for other vaccines in RMD patients. Task force members rated their agreement with draft consensus statements on a 9-point numerical scoring system, using a modified Delphi process and the RAND/University of California Los Angeles Appropriateness Method, with refinement and iteration over 2 sessions. Consensus was determined based on the distribution of ratings.Results. Despite a paucity of direct evidence, statements were developed by the task force and agreed upon with consensus to provide guidance for use of the COVID-19 vaccines, including supplemental/booster dosing, in RMD patients and to offer recommendations regarding the use and timing of immunomodulatory therapies around the time of vaccination.Conclusion. These guidance statements are intended to provide direction to rheumatology health care providers on how to best use COVID-19 vaccines and to facilitate implementation of vaccination strategies for RMD patients.Due to the rapidly expanding information and evolving evidence related to COVID-19, which may lead to modification of some guidance statements over time, it is anticipated that updated versions of this article will be published, with the version number included in the title. Readers should ensure that they are consulting the most current version.However, because of publication timelines, there may be more updated recommendations online at the ACR website that are pending journal peer review and full manuscript publication. Readers should check the ACR website at https://www.rheumatology.org/Practice-Quality/Clinical-Support/COVID-19-Guidance to confirm the ACR's most recent recommendations. The online version of the tables as they were originally published, as well as a summary of revisions over time and their location, are included in Supplementary Tables 2-6.Guidance developed and/or endorsed by the American College of Rheumatology (ACR) is intended to inform particular patterns of practice and not to dictate the care of a particular patient. The ACR considers adherence to this guidance to be voluntary, with the ultimate determination regarding its application to be made by the physician in light of each patient's individual circumstances. Guidance statements are intended to promote beneficial or desirable outcomes but cannot guarantee any specific outcome. Guidance developed or endorsed by the ACR is subject to periodic revision as warranted by the evolution of medical knowledge, technology, and practice.

show abstract

Immunogenicity of BNT162b2 mRNA SARS-CoV-2 vaccine in patients with psoriatic arthritis on TNF inhibitors

Cited by 23 publications

References 17 publications

Relapses of idiopathic inflammatory myopathies after vaccination against COVID-19: a real-life multicenter Italian study

Relapses of idiopathic inflammatory myopathies after vaccination against COVID-19: a real-life multicenter Italian study

SARS-CoV-2 vaccine humoral response in adults with Down syndrome

American College of Rheumatology Guidance for COVID‐19 Vaccination in Patients With Rheumatic and Musculoskeletal Diseases: Version 4

Contact Info

Product

Resources

About